187 related articles for article (PubMed ID: 24601650)
41. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
42. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
43. Synthesis of some N-[4-(benzothiazole-2yl) phenyl]-2-aryloxyacetamide derivatives and their anticancer activities.
Tay F; Yurttaş L; Demirayak S
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):515-20. PubMed ID: 21823837
[TBL] [Abstract][Full Text] [Related]
44. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
45. Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives.
Mokhtar AM; El-Messery SM; Ghaly MA; Hassan GS
Bioorg Chem; 2020 Nov; 104():104259. PubMed ID: 32919134
[TBL] [Abstract][Full Text] [Related]
46. Schiff's base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors.
Makawana JA; Sangani CB; Lin L; Zhu HL
Bioorg Med Chem Lett; 2014 Apr; 24(7):1734-6. PubMed ID: 24630412
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.
Alam MM; Hassan AHE; Kwon YH; Lee HJ; Kim NY; Min KH; Lee SY; Kim DH; Lee YS
Arch Pharm Res; 2018 Jan; 41(1):35-45. PubMed ID: 29094267
[TBL] [Abstract][Full Text] [Related]
49. Structure-based pharmacophore design and virtual screening for novel potential inhibitors of epidermal growth factor receptor as an approach to breast cancer chemotherapy.
Mahernia S; Hassanzadeh M; Sharifi N; Mehravi B; Paytam F; Adib M; Amanlou M
Mol Divers; 2018 Feb; 22(1):173-181. PubMed ID: 29197962
[TBL] [Abstract][Full Text] [Related]
50. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
51. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
53. Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
Wang L; Li P; Li B; Wang Y; Li J; Song L
Molecules; 2017 Sep; 22(10):. PubMed ID: 28956845
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors.
Sun J; Wang XY; Lv PC; Zhu HL
Sci Rep; 2015 Sep; 5():13934. PubMed ID: 26349898
[TBL] [Abstract][Full Text] [Related]
55. Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
Kang BR; Shan AL; Li YP; Xu J; Lu SM; Zhang SQ
Bioorg Med Chem; 2013 Nov; 21(22):6956-64. PubMed ID: 24094432
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
El-Husseiny WM; El-Sayed MA; Abdel-Aziz NI; El-Azab AS; Ahmed ER; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):507-518. PubMed ID: 29455554
[TBL] [Abstract][Full Text] [Related]
57. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of novel 1
Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
[TBL] [Abstract][Full Text] [Related]
59. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
